Autolus shares plunge on earnings miss, negative AUCATZYL margins
CAR-T therapy costs exceeded sales in launch year as net loss triples to $90.3M
Autolus Therapeutics shares fell sharply Friday after the British biotechnology company reported a fourth-quarter earnings miss and revealed that manufacturing costs for its newly launched cancer therapy exceeded sales in the critical launch year.
The London-based company reported a loss of 34 cents per share, missing analyst expectations for a 23-cent loss by nearly 48%. The miss was driven by a troubling negative gross margin: cost of sales for its AUCATZYL CAR-T therapy reached $25.3 million in the fourth quarter, exceeding product revenue of $23.3 million.
The net loss widened to $90.3 million, compared with $27.6 million in the same period a year earlier, as the company absorbed the substantial costs of scaling up production for its first commercial product. Cash, cash equivalents and marketable securities stood at $300.7 million as of December 31, down from $588 million at the end of 2024.
Autolus shares have declined approximately 29% over the past month to $1.29, trading below both the 50-day moving average of $1.52 and the 200-day average of $1.73. The stock remains far below its 52-week high of $2.70 reached earlier in the year.
The quarterly results cap a challenging but milestone-filled first commercial year for AUCATZYL (obecabtagene autoleucel), a personalized cancer therapy that reprograms patients' own immune cells to fight certain types of blood cancers. The therapy generated $74.3 million in full-year 2025 sales following its U.S. approval in November 2024 and subsequent launches in the UK and European Union.
The negative gross margin reflects the inherent challenges of commercializing CAR-T therapies, which involve extracting patients' T cells, genetically engineering them in specialized laboratories, and infusing them back into the patient. Manufacturing costs for such treatments often exceed $100,000 per patient due to specialized equipment, rigorous quality controls, and complex logistics.
"We are making significant progress in the launch of AUCATZYL and are focused on driving growth in 2026," Christian Itin, chief executive officer of Autolus, said in a statement. The company maintained its 2026 revenue guidance of $120 million to $135 million, representing growth of 62% to 82% over 2025 levels.
The company said it expects to achieve a positive gross margin during 2026 by increasing patient volumes to improve manufacturing plant utilization and implementing operational efficiencies. Autolus is evaluating automation solutions including Cellares' Cell Shuttle platform, which promises lower costs and higher throughput.
Despite the profitability challenges, analysts remain broadly optimistic about Autolus's prospects. The stock carries a consensus "Moderate Buy" rating with an average price target of $8.50, according to data from multiple brokerage firms. Individual targets range from $5 to $10, implying substantial upside from current levels.
Truist Financial upgraded shares to "strong-buy" on Thursday, the day before the earnings announcement, while HC Wainwright initiated coverage in February with a buy rating and $9 target price. However, Needham & Company reduced its price target from $11 to $10 in January, reflecting concerns about the commercial rollout pace.
The company said its cash position should fund operations into the fourth quarter of 2027, providing a runway to demonstrate improved manufacturing economics and sales momentum. Investors will be watching closely for evidence that Autolus can scale efficiently enough to achieve the positive gross margins it has promised for 2026.
Beyond the current launch, Autolus is exploring AUCATZYL in additional indications including pediatric leukemia, lupus nephritis, and progressive multiple sclerosis, which could expand the commercial opportunity if successfully developed.